Loading
companiesCompany
Genelux
Genelux is a United States-based biotechnology company running 2 late-stage cancer trials of olvimulogene nanivacirepvec and Olvimulogene nanivacirepvec in ovarian cancer and non-small-cell lung cancer.
Also called: Genelux Corporation
Overview
Genelux, based in Westlake Village, CA, the United States, is a biotechnology company. Genelux is a biopharmaceutical company developing oncolytic immunotherapies based on a modified vaccinia virus platform. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing olvimulogene nanivacirepvec and Olvimulogene nanivacirepvec in ovarian cancer and non-small-cell lung cancer. The largest, NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)), plans to enrol 186 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Westlake Village, CA, US
Scorecard
All companies#419of 1244 companies, score 8
- phase 3 +3
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 3oncolytic virus
Olvimulogene nanivacirepvec is an experimental oncolytic virus from Genelux in phase 3 trials for ovarian cancer and non-small-cell lung cancer, with its target not yet stated publicly.
cancers
drugs
Phase 3oncolytic virus
trials
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL